{{Rsnum
|rsid=730720
|Gene=CHST3
|Chromosome=10
|position=73772762
|Orientation=minus
|GMAF=0.3595
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 25.7 | 50.4 | 23.9
| HCB | 0.7 | 18.2 | 81.0
| JPT | 1.8 | 28.3 | 69.9
| YRI | 15.0 | 40.8 | 44.2
| ASW | 31.6 | 50.9 | 17.5
| CHB | 0.7 | 18.2 | 81.0
| CHD | 1.8 | 15.6 | 82.6
| GIH | 14.9 | 38.6 | 46.5
| LWK | 20.0 | 50.0 | 30.0
| MEX | 19.0 | 46.6 | 34.5
| MKK | 6.4 | 50.6 | 42.9
| TSI | 25.5 | 47.1 | 27.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs730720
|Name_s=CHST3:rs730720 A>G; NM_004273.3:c.*4533C>T
|Gene_s=CHST3
|Feature=
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: A Phenotype: The CHST3:rs730720 A variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0034 Type of association: PD; CO
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111531
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs730720
|overall_frequency_n=48
|overall_frequency_d=128
|overall_frequency=0.375
|n_genomes=35
|n_genomes_annotated=0
|n_haplomes=45
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}